Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist

Tomoyasu Tsushima, Yasutomo Nasu, Takashi Saika, Yoshio Maki, Masatoshi Noda, Bunzo Suyama, Toyoko Yamato, Hiromi Kumon

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Objective: Flare-up phenomena, such as an increase in prostate-specific antigen (PSA) and/or deterioration of symptoms, are observed in some patients undergoing gonadotropin-releasing hormone (GnRH) agonist therapy. This study was carried out to determine the optimal time for starting the administration of flutamide to prevent flare-up phenomena. Patients and Methods: Twenty-six patients with prostate cancer and elevated serum levels of PSA were randomly assigned to 5 groups. Group A patients (n = 6) were treated with a subcutaneous injection of 3.75 mg leuprorelin acetate depot alone. Group B, C, D and E patients (5 patients in each group) were treated with 375 mg/day of orally administered flutamide combined with leuprorelin. Flutamide was initiated on the day of leuprorelin injection in group B, and at 1, 2 and 4 weeks before leuprorelin injection in groups C, D and E, respectively. Serum PSA and testosterone levels were measured in each patient. Results: Pretreatment with flutamide increased the serum testosterone level, but the testosterone surge after leuprorelin administration was almost the same in all 5 treatment groups. In patients who had been treated with flutamide in combination with leuprorelin, the mean PSA level did not exceed the pretreatment levels after leuprorelin administration. The rate of decrease in PSA in the group receiving simultaneous administration of flutamide with leuprorelin showed a decline comparable to that during the period before leuprorelin administration in the flutamide pretreatment groups. Conclusion: Simultaneous administration of flutamide with a GnRH agonist is sufficient to prevent flare-up phenomena.

Original languageEnglish
Pages (from-to)135-139
Number of pages5
JournalUrologia Internationalis
Volume66
Issue number3
DOIs
Publication statusPublished - 2001

Fingerprint

Leuprolide
Flutamide
Gonadotropin-Releasing Hormone
Prostatic Neoplasms
Prostate-Specific Antigen
Testosterone
Serum
Injections
Subcutaneous Injections
Acetates

Keywords

  • Flare-up
  • Flutamide
  • Gonadotropin-releasing hormone agonist
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist. / Tsushima, Tomoyasu; Nasu, Yasutomo; Saika, Takashi; Maki, Yoshio; Noda, Masatoshi; Suyama, Bunzo; Yamato, Toyoko; Kumon, Hiromi.

In: Urologia Internationalis, Vol. 66, No. 3, 2001, p. 135-139.

Research output: Contribution to journalArticle

Tsushima, Tomoyasu ; Nasu, Yasutomo ; Saika, Takashi ; Maki, Yoshio ; Noda, Masatoshi ; Suyama, Bunzo ; Yamato, Toyoko ; Kumon, Hiromi. / Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist. In: Urologia Internationalis. 2001 ; Vol. 66, No. 3. pp. 135-139.
@article{438a3d166f90425696034737f618ff4e,
title = "Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist",
abstract = "Objective: Flare-up phenomena, such as an increase in prostate-specific antigen (PSA) and/or deterioration of symptoms, are observed in some patients undergoing gonadotropin-releasing hormone (GnRH) agonist therapy. This study was carried out to determine the optimal time for starting the administration of flutamide to prevent flare-up phenomena. Patients and Methods: Twenty-six patients with prostate cancer and elevated serum levels of PSA were randomly assigned to 5 groups. Group A patients (n = 6) were treated with a subcutaneous injection of 3.75 mg leuprorelin acetate depot alone. Group B, C, D and E patients (5 patients in each group) were treated with 375 mg/day of orally administered flutamide combined with leuprorelin. Flutamide was initiated on the day of leuprorelin injection in group B, and at 1, 2 and 4 weeks before leuprorelin injection in groups C, D and E, respectively. Serum PSA and testosterone levels were measured in each patient. Results: Pretreatment with flutamide increased the serum testosterone level, but the testosterone surge after leuprorelin administration was almost the same in all 5 treatment groups. In patients who had been treated with flutamide in combination with leuprorelin, the mean PSA level did not exceed the pretreatment levels after leuprorelin administration. The rate of decrease in PSA in the group receiving simultaneous administration of flutamide with leuprorelin showed a decline comparable to that during the period before leuprorelin administration in the flutamide pretreatment groups. Conclusion: Simultaneous administration of flutamide with a GnRH agonist is sufficient to prevent flare-up phenomena.",
keywords = "Flare-up, Flutamide, Gonadotropin-releasing hormone agonist, Prostate cancer",
author = "Tomoyasu Tsushima and Yasutomo Nasu and Takashi Saika and Yoshio Maki and Masatoshi Noda and Bunzo Suyama and Toyoko Yamato and Hiromi Kumon",
year = "2001",
doi = "10.1159/000056592",
language = "English",
volume = "66",
pages = "135--139",
journal = "Urologia Internationalis",
issn = "0042-1138",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist

AU - Tsushima, Tomoyasu

AU - Nasu, Yasutomo

AU - Saika, Takashi

AU - Maki, Yoshio

AU - Noda, Masatoshi

AU - Suyama, Bunzo

AU - Yamato, Toyoko

AU - Kumon, Hiromi

PY - 2001

Y1 - 2001

N2 - Objective: Flare-up phenomena, such as an increase in prostate-specific antigen (PSA) and/or deterioration of symptoms, are observed in some patients undergoing gonadotropin-releasing hormone (GnRH) agonist therapy. This study was carried out to determine the optimal time for starting the administration of flutamide to prevent flare-up phenomena. Patients and Methods: Twenty-six patients with prostate cancer and elevated serum levels of PSA were randomly assigned to 5 groups. Group A patients (n = 6) were treated with a subcutaneous injection of 3.75 mg leuprorelin acetate depot alone. Group B, C, D and E patients (5 patients in each group) were treated with 375 mg/day of orally administered flutamide combined with leuprorelin. Flutamide was initiated on the day of leuprorelin injection in group B, and at 1, 2 and 4 weeks before leuprorelin injection in groups C, D and E, respectively. Serum PSA and testosterone levels were measured in each patient. Results: Pretreatment with flutamide increased the serum testosterone level, but the testosterone surge after leuprorelin administration was almost the same in all 5 treatment groups. In patients who had been treated with flutamide in combination with leuprorelin, the mean PSA level did not exceed the pretreatment levels after leuprorelin administration. The rate of decrease in PSA in the group receiving simultaneous administration of flutamide with leuprorelin showed a decline comparable to that during the period before leuprorelin administration in the flutamide pretreatment groups. Conclusion: Simultaneous administration of flutamide with a GnRH agonist is sufficient to prevent flare-up phenomena.

AB - Objective: Flare-up phenomena, such as an increase in prostate-specific antigen (PSA) and/or deterioration of symptoms, are observed in some patients undergoing gonadotropin-releasing hormone (GnRH) agonist therapy. This study was carried out to determine the optimal time for starting the administration of flutamide to prevent flare-up phenomena. Patients and Methods: Twenty-six patients with prostate cancer and elevated serum levels of PSA were randomly assigned to 5 groups. Group A patients (n = 6) were treated with a subcutaneous injection of 3.75 mg leuprorelin acetate depot alone. Group B, C, D and E patients (5 patients in each group) were treated with 375 mg/day of orally administered flutamide combined with leuprorelin. Flutamide was initiated on the day of leuprorelin injection in group B, and at 1, 2 and 4 weeks before leuprorelin injection in groups C, D and E, respectively. Serum PSA and testosterone levels were measured in each patient. Results: Pretreatment with flutamide increased the serum testosterone level, but the testosterone surge after leuprorelin administration was almost the same in all 5 treatment groups. In patients who had been treated with flutamide in combination with leuprorelin, the mean PSA level did not exceed the pretreatment levels after leuprorelin administration. The rate of decrease in PSA in the group receiving simultaneous administration of flutamide with leuprorelin showed a decline comparable to that during the period before leuprorelin administration in the flutamide pretreatment groups. Conclusion: Simultaneous administration of flutamide with a GnRH agonist is sufficient to prevent flare-up phenomena.

KW - Flare-up

KW - Flutamide

KW - Gonadotropin-releasing hormone agonist

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=0035027393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035027393&partnerID=8YFLogxK

U2 - 10.1159/000056592

DO - 10.1159/000056592

M3 - Article

C2 - 11316974

AN - SCOPUS:0035027393

VL - 66

SP - 135

EP - 139

JO - Urologia Internationalis

JF - Urologia Internationalis

SN - 0042-1138

IS - 3

ER -